Opus Genetics (IRD) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Opus Genetics (NASDAQ: IRD):

• 6/18/2026 – Opus Genetics had its price target raised by Chardan Capital from $11.00 to $13.00. They now have a “buy” rating on the stock.
• 6/17/2026 – Opus Genetics had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
• 6/16/2026 – Opus Genetics had its “buy” rating reaffirmed by BTIG Research. They now have a $12.00 price target on the stock.
• 6/15/2026 – Opus Genetics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $11.00 price target on the stock.
• 6/10/2026 – Opus Genetics was upgraded by Zacks Research from “strong sell” to “hold”.
• 6/4/2026 – Opus Genetics is now covered by Guggenheim. They set a “buy” rating and a $16.00 price target on the stock.
• 6/4/2026 – Opus Genetics is now covered by Guggenheim. They set a “buy” rating and a $16.00 price target on the stock.
• 5/21/2026 – Opus Genetics is now covered by Leerink Partners. They set an “outperform” rating and a $10.00 price target on the stock.
• 5/16/2026 – Opus Genetics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/13/2026 – Opus Genetics had its price target lowered by Citizens Jmp from $12.00 to $11.00. They now have a “market outperform” rating on the stock.
• 5/12/2026 – Opus Genetics was downgraded by Zacks Research from “hold” to “strong sell”.
• 4/30/2026 – Opus Genetics had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 4/28/2026 – Opus Genetics is now covered by Citigroup Inc.. They set an “outperform” rating on the stock.
• 4/28/2026 – Opus Genetics is now covered by Citizens Jmp. They set a “market perform” rating and a $12.00 price target on the stock.

Insider Activity

In other Opus Genetics news, President Benjamin R. Yerxa sold 7,470 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $5.24, for a total value of $39,142.80. Following the sale, the president owned 711,535 shares in the company, valued at $3,728,443.40. This trade represents a 1.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,511 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.22, for a total value of $49,647.42. Following the sale, the chief executive officer directly owned 1,741,344 shares in the company, valued at approximately $9,089,815.68. This trade represents a 0.54% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 1,738,703 shares of company stock valued at $7,596,606. Corporate insiders own 11.70% of the company’s stock.

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.